MorphoSys and Incyte Announce Swissmedic Temporary Approval

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous22.03.2022 / 21:01 The issuer is solely responsible for the content of this announcement.Media ReleaseMorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed...

Related Keywords

Germany , Morges , Switzerland General , Switzerland , United Kingdom , Planegg , Bayern , Massachusetts , United States , Boston , Delaware , Canada , Swiss , Jonathan Dickinson , Mike Akimov , Incyte Europe , Nationaler Krebsbericht , Hematology Am Soc Hematol Educ Program , Practice Research Clinical Haematology , Head Of Global Drug Development , Xencor Inc , Twitter , Drug Administration , Nasdaq , Distribution Services , Exchange Commission , Cancer Research United Kingdom , Kantar Market Research , Incyte Announce Swissmedic Temporary Approval , Refractory Diffuse Largeb Cell , Executive Vice President , General Manager , Global Drug Development , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Morphosy Annual Report , Research United , Market Research , Practice Research , Corporate News , Regulatory Announcements ,